About MacroGenics, Inc.
https://www.macrogenics.comMacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.
CEO
Scott Koenig
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 18
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Leerink Partners
Outperform
Barclays
Overweight
HC Wainwright & Co.
Neutral
B. Riley Securities
Neutral
Stifel
Hold
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BELLEVUE GROUP AG
Shares:9.92M
Value:$17.66M
ARMISTICE CAPITAL, LLC
Shares:5.96M
Value:$10.61M
BLACKROCK INC.
Shares:5.4M
Value:$9.62M
Summary
Showing Top 3 of 139
About MacroGenics, Inc.
https://www.macrogenics.comMacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $72.84M ▲ | $40.83M ▼ | $16.82M ▲ | 23.09% ▲ | $0.27 ▲ | $21.95M ▲ |
| Q2-2025 | $22.24M ▲ | $50.09M ▼ | $-36.25M ▲ | -162.99% ▲ | $-0.57 ▲ | $-33.44M ▲ |
| Q1-2025 | $13.19M ▼ | $50.42M ▼ | $-41.04M ▼ | -311.07% ▼ | $-0.65 ▼ | $-39.17M ▼ |
| Q4-2024 | $17.73M ▼ | $65.08M ▲ | $-15.42M ▼ | -86.98% ▼ | $-0.25 ▼ | $-12.45M ▼ |
| Q3-2024 | $110.71M | $14.1M | $56.31M | 50.86% | $0.9 | $56.03M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $146.4M ▼ | $270.76M ▲ | $203.76M ▲ | $67M ▲ |
| Q2-2025 | $176.49M ▲ | $245.42M ▲ | $198.8M ▲ | $46.62M ▼ |
| Q1-2025 | $154.14M ▼ | $224.56M ▼ | $145.45M ▼ | $79.12M ▼ |
| Q4-2024 | $201.67M ▲ | $261.65M ▼ | $145.6M ▲ | $116.06M ▼ |
| Q3-2024 | $200.36M | $264.49M | $144.43M | $120.07M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $16.82M ▲ | $-30.19M ▲ | $-20.37M ▲ | $0 ▼ | $-50.56M ▼ | $-30.61M ▲ |
| Q2-2025 | $-36.25M ▲ | $-46.98M ▼ | $-37.64M ▼ | $69.74M ▲ | $-14.88M ▲ | $-47.7M ▼ |
| Q1-2025 | $-41.04M ▼ | $-46.89M ▼ | $9.9M ▼ | $-282K ▼ | $-37.27M ▼ | $-47.42M ▼ |
| Q4-2024 | $-15.42M ▼ | $-38.41M ▼ | $41.47M ▲ | $155K ▲ | $3.21M ▼ | $-39.03M ▼ |
| Q3-2024 | $56.31M | $60.16M | $35.6M | $-68K | $95.69M | $59.57M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Contract Manufacturing | $0 ▲ | $10.00M ▲ | $20.00M ▲ | $20.00M ▲ |
 RevenueFromCollaborativeAgreementsMember | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $50.00M ▲ |
 Product | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Scott Koenig
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 18
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Leerink Partners
Outperform
Barclays
Overweight
HC Wainwright & Co.
Neutral
B. Riley Securities
Neutral
Stifel
Hold
Grade Summary
Showing Top 5 of 5
Price Target
Institutional Ownership
BELLEVUE GROUP AG
Shares:9.92M
Value:$17.66M
ARMISTICE CAPITAL, LLC
Shares:5.96M
Value:$10.61M
BLACKROCK INC.
Shares:5.4M
Value:$9.62M
Summary
Showing Top 3 of 139